Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

67%

2 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 4
2(66.7%)
N/A
1(33.3%)
3Total
Phase 4(2)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT02728180Phase 4Unknown

Xingnaojing for Moderate-to-severe Acute Ischemic Stroke (XMAS)

Role: collaborator

NCT02641886Not ApplicableCompleted

The Study of Jian Pi Yi Shen Hua Tan Granules in Cognitive Impairment After Acute Cerebral Infarction

Role: collaborator

NCT00548223Phase 4Completed

The Secondary Prevention Trial for Ischemic Stroke With DengzhanShengmai Capsule

Role: collaborator

All 3 trials loaded